Aaron M. Williams1, MD; Steven F. Bolling1, MD; Azeem Latib2, MD
1. Department of Cardiac Surgery, University of Michigan, Ann Arbor, MI, USA; 2. Department of Cardiology, Montefiore Medical Center, Bronx, NY, USA
Although the tricuspid valve (TV) was initially considered the “forgotten valve”, the management of TV pathologies has re-emerged in recent years1. In the USA, moderate to severe tricuspid regurgitation (TR) affects nearly two million people and increases mortality, prolongs hospitalisations, and increases rates of rehospitalisation2,3,4. Furthermore, patients with TR can have significant clinical symptoms and decreased quality of life (QoL)5. Despite nearly 200,000 new diagnoses of TR per year in the USA, only 8,000 TV operations are performed annually6, highlighting the need for additional treatment options for TR patients.
Surgical intervention remains high-risk in patients with ...